Cleveland-based AnalizaDx is looking for a partner to commericialize and expand its prostate cancer-screening test, a test CEO Arnon Chait thinks is more accurate than the commonly used PSA test. And the test could be expanded to other cancers.
"A successful introduction of this test should further validate its core technology, and support further development of tests for ovarian and breast cancers," Chait told MedCity News. The company, a spin-off of the contract research organization Analiza, is hoping to find a partner in 2011, and gain FDA approval for the test, which will be conducted by the company rather than clients' labs.
AnalizaDx's test uses biomarkers to determine whether a patient has prostate cancer, rather than testing protein levels, like the prostate-specific antigen (PSA) test.
- read the MedCity News article